Last reviewed · How we verify
JNJ16269110
JNJ16269110 is a Glucagon receptor antagonist Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. It is currently in Phase 2 development for Type 2 diabetes.
JNJ16269110 is a selective and potent antagonist of the human glucagon receptor.
JNJ16269110 is a selective and potent antagonist of the human glucagon receptor. Used for Type 2 diabetes.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | JNJ16269110 |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | Glucagon receptor antagonist |
| Target | Glucagon receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
Glucagon is a hormone that raises blood glucose levels by stimulating glycogenolysis and gluconeogenesis. By blocking glucagon receptors, JNJ16269110 reduces blood glucose levels, making it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes (PHASE2)
- A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients (PHASE2)
- A Study of the Safety of R256918 in Obese Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ16269110 CI brief — competitive landscape report
- JNJ16269110 updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI
Frequently asked questions about JNJ16269110
What is JNJ16269110?
How does JNJ16269110 work?
What is JNJ16269110 used for?
Who makes JNJ16269110?
What drug class is JNJ16269110 in?
What development phase is JNJ16269110 in?
What are the side effects of JNJ16269110?
What does JNJ16269110 target?
Related
- Drug class: All Glucagon receptor antagonist drugs
- Target: All drugs targeting Glucagon receptor
- Manufacturer: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing